PND56 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

Relapsing Remitting ◽

Disease Modifying ◽

PND55 - A COST-EFFECTIVENESS ANALYSIS USING REAL-WORLD DATA FROM THE MSBASE REGISTRY: COMPARING NATALIZUMAB TO FINGOLIMOD IN PATIENTS WITH INADEQUATE RESPONSE TO DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY

Value in Health ◽

10.1016/j.jval.2018.09.2021 ◽

2018 ◽

Vol 21 ◽

pp. S338 ◽

Cited By ~ 1

Author(s):

W Herring ◽

IG Gould ◽

G Casamassima ◽

T Dort ◽

Y Zhang ◽

...

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Real World ◽

Inadequate Response ◽

Real World Data ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

A cost-effectiveness analysis using real-world data from the MSBase Registry: comparing natalizumab to fingolimod in patients with inadequate response to disease modifying therapies in relapsing-remitting multiple sclerosis in Scotland

10.26226/morressier.59a3eda8d462b8028d8951ac ◽

2017 ◽

Author(s):

Carlos Acosta

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Real World ◽

Inadequate Response ◽

Real World Data ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis

Journal of Medical Economics ◽

10.1080/13696998.2016.1247712 ◽

2016 ◽

Vol 20 (3) ◽

pp. 228-238 ◽

Cited By ~ 10

Author(s):

Luis Hernandez ◽

Shien Guo ◽

Hector Toro-Diaz ◽

Stuart Carroll ◽

Syed Feisal Syed Farooq

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain

Value in Health ◽

10.1016/j.jval.2017.08.1948 ◽

2017 ◽

Vol 20 (9) ◽

pp. A723

Author(s):

L Ruiz ◽

H Toro-Diaz ◽

C Cele ◽

L Hernandez ◽

A Harrington

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

First Line ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

PND51 Cladribine Tablets (CT) Versus Other Disease-Modifying Therapies in the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) - Cost-Effectiveness Analysis.

Value in Health ◽

10.1016/j.jval.2020.08.1376 ◽

2020 ◽

Vol 23 ◽

pp. S632

Author(s):

P. Zięba ◽

D. Pawlik ◽

J. Wieczorek ◽

R. Wojcik ◽

M.P. Kaczor

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Patients with Inadequate Response to Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis in the United Kingdom

PharmacoEconomics ◽

10.1007/s40273-021-01106-6 ◽

2021 ◽

Author(s):

Timothy Spelman ◽

William L. Herring ◽

Yuanhui Zhang ◽

Michael Tempest ◽

Isobel Pearson ◽

...

Keyword(s):

Multiple Sclerosis ◽

United Kingdom ◽

Cost Effectiveness ◽

Comparative Effectiveness ◽

Inadequate Response ◽

The United Kingdom ◽

Relapsing Remitting ◽

Disease Modifying ◽

Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations

PharmacoEconomics ◽

10.1007/s40273-018-0683-9 ◽

2018 ◽

Vol 36 (10) ◽

pp. 1223-1252 ◽

Cited By ~ 7

Author(s):

Luis Hernandez ◽

Malinda O’Donnell ◽

Maarten Postma

Keyword(s):

Multiple Sclerosis ◽

Systematic Review ◽

Cost Effectiveness ◽

Economic Evaluations ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis

Journal of Medical Economics ◽

10.1080/13696998.2016.1258366 ◽

2016 ◽

Vol 20 (3) ◽

pp. 297-302 ◽

Cited By ~ 12

Author(s):

Duygu Bozkaya ◽

Terrie Livingston ◽

Kristen Migliaccio-Walle ◽

Tanner Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽

A Cost-Effectiveness Analysis of Fingolimod Versus Dimethyl Fumarate As A Second-Line Disease Modifying Treatment In Patients With Highly Active Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.09.2470 ◽

2015 ◽

Vol 18 (7) ◽

pp. A758 ◽

Cited By ~ 2

Author(s):

M Raikou ◽

M Kalogeropoulou ◽

G Rombopoulos

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Dimethyl Fumarate ◽

Second Line ◽

Highly Active ◽

Effectiveness Analysis ◽

Relapsing Remitting ◽

Disease Modifying ◽

Disease Modifying Treatment ◽

The Cost-Effectiveness of Disease Modifying Therapies for The Treatment of Relapsing-Remitting Multiple Sclerosis

Value in Health ◽

10.1016/j.jval.2015.03.1653 ◽

2015 ◽

Vol 18 (3) ◽

pp. A283 ◽

Cited By ~ 2

Author(s):

D. Bozkaya ◽

T.P. Livingston ◽

K. Migliaccio-Walle ◽

S. Mehta ◽

T. Odom

Keyword(s):

Multiple Sclerosis ◽

Cost Effectiveness ◽

Relapsing Remitting ◽

Disease Modifying ◽

The Cost ◽